$96.5 Million Generic Payout Latest Trouble for Mylan February 15, 2017 By Christine Blank A $96.5 million settlement is the latest in a series of pricing and competition issues Mylan has faced in the past year. How New Biosimilars Will Impact the Market February 15, 2017 By Christine Blank More biosimilars are coming onto the market , including competitors for Remicade and Neulasta. CVS, Cigna on board with generic EpiPens The urgent need for a less-expensive epinephrine auto-injector is now being addressed. Generics and biosimilars, key to Trump drug price concerns If pharma is “getting away with murder” with drug pricing, more generic and biosimilars can help control costs, says this group. Issues about biosimilar substitution At a time when biosimilars are of strong interest to insurers and health care systems for cost control, physicians are not rushing to issue a blank check for their substitution. Details here. Pharmacy prices vary widely for generic heart drugs The prices of heart failure drugs at retail pharmacies vary widely, and uninsured patients may not be able to afford them, researchers have found. Generic drugs save U.S. $227 billion Generic drugs produced $227 billion in savings for the U.S. healthcare system in 2015 Why Remicade biosimilar sales will grow in the U.S. Two new biosimilar announcements are expected to increase the uptake of the biosimilar infliximab to Johnson & Johnson’s Remicade for rheumatoid arthritis, Crohn’s disease, and other inflammatory conditions. Industry pushes for faster generic approvals as costs rise Generic drugmakers and others are pushing for faster FDA approval of generics. Will docs prescribe the new RA biosimilars? While FDA recently approved two new biosimilars for rheumatoid arthritis and other inflammatory diseases, questions remain about how quickly physicians and patients will embrace the new drugs.